Genomic Health

Genomic Health

Genomic Health Logo

Genomic Health, Inc. was a company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer. The company was founded in 2000 and was headquartered in Redwood City, California. Genomic Health was known for its flagship product, the Oncotype DX test, which was used to guide treatment decisions for breast, colon, and prostate cancer patients.

History

Genomic Health was established with the goal of improving cancer treatment through the use of genomic information. The company aimed to provide personalized medicine solutions by analyzing the genetic makeup of tumors to predict how they would respond to various treatments. Over the years, Genomic Health expanded its product offerings and became a leader in the field of genomics and personalized medicine.

In 2019, Genomic Health was acquired by Exact Sciences Corporation, a company known for its non-invasive cancer screening tests. This acquisition allowed Exact Sciences to expand its portfolio and enhance its capabilities in cancer diagnostics.

Products

Oncotype DX

The Oncotype DX test was Genomic Health's most well-known product. It was a genomic test that analyzed the expression of a group of cancer-related genes in a tumor sample. The test provided a Recurrence Score, which helped predict the likelihood of cancer recurrence and the potential benefit of chemotherapy for patients with early-stage breast cancer. The Oncotype DX test was also adapted for use in colon and prostate cancer.

Other Tests

In addition to the Oncotype DX test, Genomic Health developed other genomic tests aimed at improving cancer treatment. These tests were designed to provide insights into the biology of a patient's cancer, helping to tailor treatment plans to the individual's specific needs.

Impact on Cancer Treatment

Genomic Health's tests played a significant role in the shift towards personalized medicine in oncology. By providing detailed genomic information about a patient's tumor, these tests enabled more precise treatment decisions, potentially improving outcomes and reducing unnecessary treatments. The company's work contributed to a broader understanding of the genetic factors involved in cancer progression and response to therapy.

Acquisition by Exact Sciences

In July 2019, Exact Sciences announced its intention to acquire Genomic Health in a deal valued at approximately $2.8 billion. The acquisition was completed in November 2019, creating a leading global cancer diagnostics company. The merger combined Exact Sciences' expertise in early cancer detection with Genomic Health's strength in genomic testing, aiming to advance the field of cancer diagnostics and improve patient care.

Related Pages

• Genomics
• Personalized medicine
• Cancer diagnostics
• Exact Sciences Corporation